Table 5. Clinical and pathological characteristics of patients in the validation cohort.
| Urine cohort | |||
| Low-Risk | High-Risk | ||
| n | 14 | 22 | |
| Age | Median | 63 | 63 |
| (yrs) | Range | 45–71 | 49–79 |
| Follow-up | Median | 3.47 | 3.84 |
| (yrs) | Range | 2.79–5.13 | 2.77–5.41 |
| Prostate Weight | Median | 60 | 50 |
| (g) | Range | 28–78 | 31–87 |
| Gleason Grade (%) | 6 | 14 (100) | 0 (0) |
| 7 (3+4) | 0 (0) | 0 (0) | |
| 7 (4+3) | 0 (0) | 1 (4) | |
| 8 | 0 (0) | 3 (14) | |
| 9 (4+5) | 0 (0) | 15 (68) | |
| 9 (5+4) | 0 (0) | 3 (14) | |
| Tumour Volume | Median | .2000 | 10.65 |
| (cc) | Range | 0.10–0.90 | 2.50–28.70 |
| pT stage (%) | pT2a | 4 (29) | 0 (0) |
| pT2b | 0 (0) | 0 (0) | |
| pT2c | 10 (71) | 1 (5) | |
| pT3a | 0 (0) | 10 (45) | |
| pT3b | 0 (0) | 11 (50) | |
| EPE (%) | Present | 0 (0) | 21 (96) |
| Absent | 14 (100) | 1 (4) | |
| SV Invasion (%) | Present | 0 (0) | 10 (45) |
| Absent | 14 (100) | 12 (55) | |
| PN Invasion (%) | Present | 3 (21) | 22 (100) |
| Absent | 11 (79) | 0 (0) | |
| LV Invasion (%) | Present | 0 (0) | 16 (73) |
| Absent | 14 (100) | 6 (27) | |
| Multifocal (%) | Yes | 12 (86) | 13 (59) |
| No | 2 (14) | 9 (41) | |
| Surgical Margins (%) | Positive | 0 (0) | 16 (73) |
| Negative | 14 (100) | 6 (27) | |
| Metastatic Disease (%) | Yes | 0 (0) | 0 (0) |
| No | 14 (100) | 22 (100) | |